I wasn’t invested at the time, but I have a question regarding the talk about Pestell raising questions at an i opportune time, concerning Leronlimab‘s safety profile. Maybe some of you could shed some light on that because it’s hard to make sense of such an accusation given Leronlimab’s safety profile. Was he really concerned about Leronlimab’s safety? And what was the effect of his actions at the time? What was the context? Was the submission of a BLA taking place? Could it be rather, that he might have been concerned the application did not contain the aggregated safety data that we are scrambling to assemble from the audited data? or is it something else? Would someone who knows the truth about this please tell it the way it happened. Thank you